title: Low dose intraarterial thrombolysis with tissue plasminogen activator: does it deliver as promised?
abstract: The widespread use of intraarterial thrombolytic therapy has been based on perceived benefits over operative treatment and the downgrading of the magnitude of subsequent surgery. Thirty-three patients who had thrombolysis for peripheral artery occlusion were retrospectively analyzed at St. James's Hospital from 1991 to 1997. One patient received streptokinase unsuccessfully. Five other patient's records were inadequate for analysis. Twenty-seven patient's notes were analyzed for risk, duration of occlusion, duration of treatment, dosage of tissue plasminogen activator (tPA) and conduits thrombolysed. There were 15 males and 12 females. The mean age was 62 years (range, 20-87). Fourteen were current or reformed smokers. Five were diabetic. Indications for treatment included acute graft occlusion (n=13), embolus (n=6), and primary and secondary arterial thrombosis (n=8). Duration of occlusion was less than 24 hours in seven, 1 to 7 days in ten, and more than 7 days in ten patients. Twelve (44.44%) patients had complete clot lysis, four (14.81%) had partial clearance, and 11 (40.74%) remained occluded. Eight (29.63%) had serious complications including one death. Eighteen (66.66%) patients needed further surgical intervention to maintain graft patency. Data were analyzed using the chi-square and pooled t test. No significant difference was observed in results from thrombolysis from different conduits, gender, etiology, or smoking history. Increased duration of tPA administration was associated with an increased risk of failure. Administration of total dosages greater than 60 mg was associated with a higher risk of failure. Diabetics had a poor outcome (p=0.0520). Only 44 % of patients successfully underwent lysis. A primary surgical option may be a more sensible course than lysis, given that the vast majority of patients ended up having surgery anyway.
authors.affiliation: Department of Vascular and Endovascular Surgery, St. James's Hospital, Dublin. pmadhavan@stjames.ie
authors.forename: P
authors.initials: P
authors.lastname: Madhavan
authors.forename: S
authors.initials: S
authors.lastname: Sultan
authors.forename: C O
authors.initials: CO
authors.lastname: McDonnell
authors.forename: J P
authors.initials: JP
authors.lastname: Cowman
authors.forename: M P
authors.initials: MP
authors.lastname: Colgan
authors.forename: N
authors.initials: N
authors.lastname: McEniff
authors.forename: M
authors.initials: M
authors.lastname: Molloy
authors.forename: D J
authors.initials: DJ
authors.lastname: Moore
authors.forename: G
authors.initials: G
authors.lastname: Shanik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D017541:Aneurysm, False / Q000209:etiology; D048909:Diabetes Complications; D004305:Dose-Response Relationship, Drug; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006406:Hematoma / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator